Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro

Brain Research Bulletin

Volumn 87, Issue 4-5, 2012, Pages 397-405

  Colle, Dirleise ^a   Hartwig, Juliana M ^a   Antunes Soares, Félix A ^b   Farina, Marcelo ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

3 Nitropropionic acid; Huntington's disease; Mitochondrial dysfunction; Oxidative stress; Probucol; Quinolinic acid

Indexed keywords

3 NITROPROPIONIC ACID; CALCIUM ION; DIZOCILPINE; PROBUCOL; QUINOLINIC ACID; REACTIVE OXYGEN METABOLITE; SUCCINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN SLICE; CALCIUM METABOLISM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; EXCITOTOXICITY; HUNTINGTON CHOREA; IN VITRO STUDY; LIPID PEROXIDATION; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIOXIDANTS; CONVULSANTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; LIPID PEROXIDATION; MALE; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; NITRO COMPOUNDS; ORGAN CULTURE TECHNIQUES; OXIDATIVE STRESS; PROBUCOL; PROPIONIC ACIDS; QUINOLINIC ACID; RATS; RATS, WISTAR;

EID: 84857916858     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.01.003     Document Type: Article

References (77)

1. Albin R.L., Greenamyre J.T. Alternative excitotoxic hypotheses. Neurology 1992, 42(4):733-738.
2. Ali S.F., LeBel C.P., Bondy S.C. Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. Neurotoxicology 1992, 13:637-648.
3. Andreassen O.A., Dedeojlu A., Ferrante R.J., Jenkins B.G., Thomas M. Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 2001, 8:479-491.
4. Avila D.S., Gubert P., Palma A., Colle D., Alves D., Nogueira C.W., Rocha J.B., Soares F.A. An organotellurium compound with antioxidant activity against excitotoxic agents without neurotoxic effects in brain of rats. Brain Res. Bull. 2008, 76:114-123.
5. Beal M.F., Hyman B.T., Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases. Trends Neurosci. 1993, 16:125-131.
6. Behrens M.I., Koh J., Canzoniero L.M., Sensi S.L., Csernansky C.A., Choi D.W. 3-Nitropropionic acid induces apoptosis in cultured striatal and cortical neurons. Neuroreport 1995, 6:545-548.
7. Behrens P.F., Franz P., Woodman B., Lindenberg K.S., Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 2002, 125:1908-1922.
8. Benchoua A., Trioulier Y.I., Zala D., Gaillard M.C., Lefort N., Dufour N., Saudou F., Elalouf J.M., Hirsch E., Hantraye P., Déglon N., Brouillet E. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell 2006, 17:1652-1663.
9. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 1999, 59:427-468.
10. Browne S.E., Beal M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal. 2006, 8:2061-2073.
11. Buckley M.M., Goa K.L., Price A.H., Brogden R.N. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs 1989, 37:761-800.
12. Chen C. Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. Chang Gung Med. J. 2011, 34:135-152.
13. Choi D.W. Cerebral hypoxia: some new approaches and unanswered questions. J. Neurosci. 1990, 10:2493-2501.
14. Del Río P., Massieu L. Mild mitochondrial inhibition in vivo enhances glutamate-induced neuronal damage through calpain but not caspase activation: role of ionotropic glutamate receptors. Exp. Neurol. 2008, 212:179-188.
15. Del Río P., Montinel T., Chagoya V., Massieu L. Exacebation of excitotoxic neuronal death induced during mitochondrial inhibition in vivo: relation to energy imbalance or ATP depletion?. Neuroscience 2007, 146:1561-1570.
16. Elinos-Calderón D., Robledo-Arratia Y., Pérez-De La Cruz V., Maldonado P.D., Galván-Arzate S., Pedraza-Chaverrí J., Santamaría A. Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine. J. Neural Transm. 2010, 117(1):35-44.
17. Ermak G., Davies K.J.A. Calcium and oxidative stress: from cell signaling to cell death. Mol. Immunol. 2001, 38:713-721.
18. Farina M., Campos F., Vendrell I., Berenguer J., Barzi M., Pons S., Suñol C. Probucol increases glutathione peroxidase-1 activity and displays long-lasting protection against methylmercury toxicity in cerebellar granule cells. Toxicol. Sci. 2009, 112(2):416-426.
19. Fink S.L., HO D.Y., Sapolsky R.M. Energy and glutamate dependency of 3-nitropropionic acid neurotoxicity in culture. Exp. Neurol. 1996, 138:298-304.
20. Giampà C., Patassini S., Borreca A., Laurenti D., Marullo F., Bernardi G., Menniti F.S., Fusco F.R. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiol. Dis. 2009, 34:450-456.
21. Greene J.G., Sheu S.S., Gross R.A., Greenamyre J.T. 3-Nitropropionic acid exacerbates N-methyl-d-aspartate toxicity in striatal culture by multiple mechanisms. Neuroscience 1998, 84:503-510.
22. Guidetti P., Luthi-Carter R.E., Augood S.J., Schwarcza R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 2004, 17:455-461.
23. Huang L., Sun G., Cobessi D., Wang A., Shen J.T., Tung E.Y., Anderson V.E., Berry E.A. 3-Nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J. Biol. Chem. 2006, 281(9):5965-5972.
24. 2+ entry during NMDA receptor activation. FASEB J. 2006, 20:1021-1023.
25. Jang S., Jeong H.S., Parka J.S., Kim Y.S., Jin C.Y., Seol M.B., Kim B.C., Lee M.C. Neuroprotective effects of (-)-epigallocatechin-3-gallate against quinolinic acid-induced excitotoxicity via PI3K pathway and NO inhibition. Brain Res. 2010, 1313:25-33.
26. Kalonia H., Kumar A. Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats. Life Sci. 2011, 88:784-791.
27. Kalonia H., Kumar P., Nehru B., Kumar A. Neuroprotective effect of MK-801 against intra-striatal quinolinic acid induced behavioral, oxidative stress and cellular alterations in rats. Indian J. Exp. Biol. 2009, 47(11):880-892.
28. Kalonia H., Kumar P., Kumar A., Nehru B. Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats. Neurotoxicology 2010, 31:195-203.
29. Kalonia H., Kumar P., Kumar A. Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats. Brain Res. 2011, 1372:115-126.
30. Kasparová S., Sumbalová Z., Bystrický P., Kucharská J., Liptaj T., Mlynárik V., Gvozdjáková A. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem. Int. 2005, 48(2):93-99.
31. Kumar P., Kumar A. Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunction in rat brain. Prog. Neuropsycopharmacol. Prog. Neuropsychopharmacol. Biol. Psych. 2009, 33(1):100-108.
32. Kumar P., Padis S.S.V., Naidu P.S., Kumar A. Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam. Clin. Pharmacol. 2007, 21:297-306.
33. Kumar P., Kalonia H., Kumar A. Huntington's disease: pathogenesis to animal models. Pharmacol. Rep. 2010, 62:1-14.
34. Kumar P., Kalonia H., Kumar A. Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofenole. Br. J. Pharmacol. 2011, 162(2b):644-654.
35. Lee W.T., Chang C. Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease. Prog. Neurobiol. 2004, 72:87-110.
36. Lee W.T., Yin H.S., Shen Y.Z. The mechanisms of neuronal death produced by mitochondrial toxin 3-nitropropionic acid: the roles of N-methyl-d-aspartate glutamate receptors and mitochondrial calcium overload. Neuroscience 2002, 112:707-716.
37. Li X.J., Li S. Proteasomal dysfunction in aging and Huntington disease. Neurobiol. Dis. 2011, 43:4-8.
38. Liot G., Bossy B., Lubitz S., Kushnareva Y., Sejbuk N., Bossy-Wetzel E. Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA- and ROS-dependent pathway. Cell Death Differ. 2009, 16:899-909.
39. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
40. Massieu L., Del Río P., Montiel T. Neurotoxicity of glutamate uptake inhibition in vivo: correlation with succinate dehydrogenase activity and prevention by energy substrates. Neuroscience 2001, 106(4):669-677.
41. Matyja E. Intracellular calcium overload in a model of quinolinic acid neurotoxicity in organotypic culture of rat hippocampus; inhibited by nimodipine. Folia Neuropathol. 1997, 35:8-17.
42. Mochel F., Haller R.G. Energy deficit in Huntington disease: why it matters. J. Clin. Invest. 2011, 121(2):493-499.
43. MAPK signaling. Neurochem. Res. 2008, 33:27-36.
44. Montilla P., Túnez I., Muñoz M.C., Salcedo M., Feijóo M., Muñoz-Castañeda J.R., Bujalance I. Effect of glucocorticoids on 3-nitropropionic acid-induced oxidative stressing synaptosomes. Eur. J. Pharmacol. 2004, 488:19-25.
45. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65(1-2):55-63.
46. Novelli A., Reilly J.A., Lysko P.G., Henneberry R.C. Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced. Brain Res. 1988, 451:205-212.
47. Oliveira I.J.L., Molz S., Souza D.O., Tasca C.I. Neuroprotective effect of GMP in hippocampal slices submitted to an in vitro model of ischemia. Cell. Mol. Neurobiol. 2002, 22(3):335-344.
48. Pang Z., Geddes J.W. Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. J. Neurosci. 1997, 7:3064-3073.
49. Park S.Y., Lee J.H., Kim C.D., Rhim B.Y., Hong K.W., Lee W.S. Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats. Brain Res. 2007, 1157:112-120.
50. Pereira R.P., Fachinetto R., de Souza Prestes A., Puntel R.L., Santos da Silva G.N., Heinzmann B.M., Boschetti T.K., Athayde M.L., Bürger M.E., Morel A.F., Morsch V.M., Rocha J.B. Antioxidant effects of different extracts from Melissa officinalis, Matricaria recutita and Cymbopogon citratus. Neurochem. Res. 2009, 34(5):973-983.
51. Pérez-De La Cruz V., Santamaria A. Integrative hypothesis for Huntington's Disease: a brief review of experimental evidence. Physiol. Res. 2007, 56:513-526.
52. Pérez-De La Cruz V., Konigsberg M., Pedraza-Chaverri J., Herrera-Mundo N., Díaz-Muñoz M., Morán J., Fortoul-van der Goes T., Rondán-Zárate A., Maldonado P.D., Ali S.F., Santamaría A. Cytoplasmic calcium mediates oxidative damage in an excitotoxic/energetic deficit synergic model in rats. Eur. J. Neurosci. 2008, 27:1075-1085.
53. Pérez-De La Cruz V., Elinos-Calderón D., Carrillo-Mora P., Silva-Adaya D., Konigsberg M., Morán J., Ali S.F., Chánez-Cárdenas M.E., Pérez-De La Cruz G., Santamaría A. Time-course correlation of early toxic events in three models of striatal damage: modulation by proteases inhibition. Neurochem. Int. 2010, 56:834-842.
54. Puntel R.L., Nogueira C.W., Rocha J.B. N-methyl-d-aspartate receptors are involved in the quinolinic acid, but not in the malonate pro-oxidative activity in vitro. Neurochem. Res. 2005, 30(3):417-424.
55. Ramaswamy S., McBride J.L., Kordower J.H. Animal models of Huntington's disease. ILAR J. 2007, 48(4):356-373.
56. Rekik L., Daguin-Nerrière V., Petit J., Brachet P. 3γ-Aminobutyric acid type B receptor changes in the rat striatum and substantia nigra following intrastriatal quinolinic acid lesions. J. Neurosci. Res. 2011, 89:524-535.
57. Ríos C., Santamaría A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res. 1991, 16:1139-1143.
58. Roos R.A.C. Huntington's disease: a clinical review. Orphanet J. Rare Dis. 2010, 5(40):1-8.
59. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
60. Rossignol J., Boyer C., Lévèque X., Fink K.D., Thinard R., Blanchard F., Dunbar G.L., Lescaudron L. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes. Behav. Brain Res. 2011, 217:369-378.
61. Santamaría A., Galván-Arzate S., Lisy V., Ali S.F., Duhart H.M., Osorio-Rico L., Rios C., St'Astny F. Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport 2001, 12:871-874.
62. Schuck P.F., Tonin A., Ferreira G.C., Rosa R.B., Latini A., Balestro F., Perry M.L.S., Wannmacher C.M.D., Wyse A.T.S., Wajner M. In vitro effect of quinolinic acid on energy metabolism in brain of young rats. Neurosci. Res. 2007, 57:277-288.
63. Schwarcz R., Whetsell W.O.J.R., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219:316-319.
64. Silva-Adaya D., Pérez-De La Cruz V., Herrera-Mundo M.N., Mendoza-Macedo K., Villeda-Hernández J., Binienda Z., Ali S.F., Santamaría A. Excitotoxic damage, disrupted energy metabolism and oxidative stress in the rat brain: antioxidant and neuroprotective effects of l-carnitine. J. Neurochem. 2008, 105:677-689.
65. Southwell A.L., Patterson P.H. Gene therapy in mouse models of Huntington disease. Neuroscientist 2011, 17(2):153-162.
66. Stone T.W., Perkins M.N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 1981, 72:411-412.
67. Stone T.W., Behan W.M., MacDonald M., Darlington L.G. Possible mediation of quinolinic acid-induced hippocampal damage by reactive oxygen species. Amino Acids 2000, 19(1):275-281.
68. Tasset I., Pérez-De La Cruz V., Elinos-Calderón D., Carrillo-Mora P., González-Herrera I.G., Luna-López A., Konigsberg M., Pedraza-Chaverrí J., Maldonado P., Ali S.F., Túnez I., Santamaría A. Protective effect of tert-butylhydroquinone on the quinolinic-acid-induced toxicity in rat striatal slices: role of the Nrf2-antioxidant response element pathway. Neurosignals 2010, 18(1):24-31.
69. Tavares R.G., Tasca C.I., Santos C.E.S., Alves L.B., Porciúncula L.O., Emanuelli T., Souza D.O. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem. Int. 2002, 40:621-627.
70. Túnez I., Tasset I., Pérez-De La Cruz V., Santamaría A. 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future. Molecules 2010, 15:878-916.
71. Vamos E., Pardutz A., Klivenyi P., Toldi J., Vecsei L. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J. Neurol. Sci. 2009, 283:21-27.
72. Wang S., Michaelis E.K. Selective neuronal vulnerability to oxidative stress in the brain. Front. Aging Neurosci. 2010, 2:1-13.
73. Witting P.K., Wu B.J., Raftery M., Southwell-Keely P., Stocker R. Probucol protects against hypochlorite-induced endothelial dysfunction: indentification of a novel pathway of probucol oxidation to a biologically active intermediate. J. Biol. Chem. 2005, 280(16):15612-15618.
74. Yamashita S., Matsuzawa Y. Where are we with probucol: a new life for an old drug?. Atherosclerosis 2009, 207:16-23.
75. Yamashita S., Hbujo H., Arai H., Harada-Shiba M., Matsui S., Fukushima M., Saito Y., Kita T., Matsuzawa Y. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J. Atheroscler. Thromb. 2008, 15(6):292-303.
76. Yang L., Calingasan N.Y., Wille E.J., Cormier K., Smith K., Ferrante R.J., Beal M.F. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J. Neurochem. 2009, 109(5):1427-1439.
77. Zadóri D., Klivényi P., Vámos E., Fulo F., Toldi J., Vécsei L. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J. Neural. Transm. 2009, 116:1403-1409.